Pembrolizumab

Extended indication	Breast cancer, metastatic triple negative.
Therapeutic value	No judgement
Total cost	5,000,000.00

Product

Active substance	Pembrolizumab
Domain	Oncology and Hematology
Main indication	Breast cancer
Extended indication	Breast cancer, metastatic triple negative.
Proprietary name	Keytruda
Manufacturer	MSD
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)

Registration

Registration route	Centralised (EMA)
Expected Registration	December 2018
Orphan drug	No
Additional remarks	Dit is een indicatie-uitbreiding.

Therapeutic value

Therapeutic value	No judgement
Duration of treatment	Not found

Expected patient volume per year

Patient volume	< 100 Market share is generally not included unless otherwise stated.
References	NKR
Additional remarks	NKR 2015: 100 diagnoses mammacarcinoom HR-, HER-, stadium 4

Patient volume

< 100

Market share is generally not included unless otherwise stated.

References

NKR

Additional remarks

NKR 2015: 100 diagnoses mammacarcinoom HR-, HER-, stadium 4

Expected cost per patient per year

Cost	40,000.00 - 60,000.00
References	Medicijnkosten.nl
Additional remarks	€ 3.355,96 per injectieflacon 25MG/ML FL 4ML (oplossing). € 1677,98 per injectieflacon 50MG FL (poeder)

Potential total cost per year

Total cost	5,000,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Total cost

5,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.